Inozyme Pharma, Inc. announced CEO Transition. Axel Bolte, MSc, MBA, the Company's founding CEO will retire and continue to work with Inozyme as a senior advisor and serve on the Board. Douglas A. Treco, Ph.D., an industry veteran and Chairman of the Board, will succeed Mr. Bolte as the CEO of the Company, effective April 1, 2023.

Dr. Treco was co-founder, president, and chief executive officer of Ra Pharmaceuticals, Inc. where he oversaw the discovery and development of zilucoplan in myasthenia gravis, which is currently under review for marketing approval in the United States and European Union. Previously, he co-founded Transkaryotic Therapies, Inc., where he directed research and development efforts which led to the approval of Replagal, Elaprase, Dynepo, and Vpriv. Dr. Treco is a member of the Board of Directors of CRISPR Therapeutics AG.